Savant Capital LLC Decreases Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Savant Capital LLC cut its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 52.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,585 shares of the biotechnology company’s stock after selling 11,477 shares during the quarter. Savant Capital LLC’s holdings in BioCryst Pharmaceuticals were worth $80,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. R Squared Ltd purchased a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $48,000. Mirae Asset Global Investments Co. Ltd. boosted its position in BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,322 shares in the last quarter. KBC Group NV boosted its position in BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 4,537 shares in the last quarter. Quantinno Capital Management LP purchased a new stake in BioCryst Pharmaceuticals during the third quarter worth $82,000. Finally, SkyView Investment Advisors LLC boosted its position in BioCryst Pharmaceuticals by 30.0% during the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 3,000 shares in the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on BCRX. JMP Securities reiterated a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Barclays boosted their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Needham & Company LLC boosted their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Finally, Evercore ISI boosted their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $15.50.

BioCryst Pharmaceuticals Stock Up 0.3 %

NASDAQ BCRX opened at $9.39 on Thursday. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $9.48. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -15.39 and a beta of 1.75. The business has a fifty day moving average of $7.94 and a 200-day moving average of $7.81.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.